Evidence map›Paper›PMID 20979557›Full record

ReviewExpert review of clinical immunology2010

Recent advances in the treatment of eosinophilic esophagitis.

Shauna Schroeder, Dan Atkins, Glenn T Furuta

Abstract readReview
In one paragraph

Review in Expert review of clinical immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Shauna SchroederUniversity of Colorado Denver School of Medicine, Denver, CO, USA; The Children's Hospital Denver, 13123 East 16th Avenue, B290, Aurora, CO 80016, USA.
Dan Atkins
Glenn T Furuta
Children's Hospital Colorado · USUniversity of Colorado Denver · US

Funding

Institutional Training Grant in Pediatric GastroenterologyT32DK067009 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI RONALD J. SOKOL, Edwin Fulco de Zoeten · 2005 to 2026
$7.1M
NIDDK NIH HHS T32 DK067009
6 · The paper itself

Abstract

First described nearly 20 years ago, eosinophilic esophagitis (EoE) is an inflammatory disease of the esophagus characterized by eosinophilic infiltration of the esophageal epithelium. Over 50% of the current literature on EoE has been published in the last 3 years, signaling both a rising incidence and increased recognition of this disorder. Treatment options available for patients with EoE include dietary management and/or pharmacologic therapy. An individualized approach to treatment is preferred, with an emphasis on patient-parental preference. The objective of this article is to discuss the current and future treatment options for EoE.

Indexed as

ImmunotherapyAntibodies, MonoclonalDiet TherapyEosinophilic EsophagitisHumansInterleukin-13Interleukin-5Mucous MembranePatient PreferencePrecision MedicineProton Pump InhibitorsTh1-Th2 BalanceAntibodies, MonoclonalInterleukin-13Interleukin-5Proton Pump Inhibitors

Identifiers

PMID20979557
PMCPMC3816102
OpenAlexW2096177384

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.